MiMedx Group (MDXG) Cantor Global Healthcare Conference 2025 summary

Market overview and business positioning

• Focuses on wound and surgical healing solutions, addressing a large and growing patient population, especially among Medicare beneficiaries.

• Products are derived from birth tissue, mainly placenta, and processed using proprietary technology.

• Vertically integrated operations with significant manufacturing headroom and a robust direct sales force.

• Revenue split is approximately two-thirds wound care and one-third surgical, both segments growing.

• Strategic priorities are aimed at expanding patient reach, business growth, and long-term shareholder value.

Regulatory and reimbursement environment

• Recent CMS changes to reimbursement methodology were positively received, moving to a flat price per square centimeter and application fee.

• Adjustments in both the Physician Fee Schedule and OPPS are expected to correct previous payment imbalances.

• Company is preparing for the new reimbursement structure by adjusting product offerings and manufacturing capacity.

• Anticipates a shift back to more reasonably priced products post-January 1, aligning with new reimbursement constraints.

Product innovation and pipeline

• Surgical products are expanding from ancillary use to being integrated into procedures, with growing evidence supporting efficacy.

• Portfolio includes amniotic tissue, xenografts, and plans to expand via partnerships or acquisitions, especially in xenograft and synthetic technologies.

• EPIXPRESS, a new fenestrated sheet product, is set to launch, addressing fluid retention in wound care.

• R&D pipeline is robust, focusing on unique handling characteristics and unmet clinical needs.

• Emphasis on generating clinical evidence to support product adoption and reimbursement.